Log In
BCIQ
Print this Print this
 

BTA585

Also known as: BTA-C585

  Manage Alerts
Collapse Summary General Information
Company Aviragen Therapeutics Inc.
DescriptionRSV F protein inhibitor
Molecular Target RSV F protein
Mechanism of ActionViral fusion inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsTreat respiratory syncytial virus (RSV) A and B infection; Treat respiratory syncytial virus (RSV) infection
Regulatory Designation U.S. - Fast Track (Treat respiratory syncytial virus (RSV) infection)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today